Li Lei, Ren Jian-Xun, Lin Zhi-Rong, Shi Yue, Ma Yan-Lei, Liu Jian-Xun
Institute of Basic Medical Sciences of Xiyuan hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Beijing Key Laboratory of Chinese Materia Pharmacology, Beijing 100091, China.
Zhongguo Zhong Yao Za Zhi. 2016 Mar;41(5):910-916. doi: 10.4268/cjcmm20160525.
Salvianolic acid A (SAA), one of the major active water-soluble salvianolic acids of traditional Chinese medicine Salvia miltiorrhiza Bunge, has been reported to be effective on anti-myocardial ischemia, anti-oxidation and anti-thrombus. This study aimed to investigate appropriate administration route on dogs with acute myocardial ischemia(AMI). Twenty-four dogs were randomized into four groups (n=6), model, oral administration of SAA (8 mg•kg⁻¹), intravenous administration of SAA (4 mg•kg⁻¹), intravenous administration of Herbesser(0.5 mg•kg⁻¹) as positive drug group. AMI model was established by ligating left anterior descending coronary arteries(LAD) of dogs. Changes of ST segment were determined by epicardial electrocardiogram(ECG), coronary blood flow (CBF) and myocardial oxygen consumption were measured by ultrasonic Doppler flow meter, serum creatine kinase (CK) and lactate dehydrogenase (LDH) were observed by fully automatic biochemical analyser. Myocardial infarct size was assessed by nitro blue tetrazolium (NBT) staining. Both oral and intravenous administration of SAA reduced the myocardial infarct area/left ventricle area significantly [(16.73±6.52)% and (13.19±2.38)%, compared with (24.35±4.89)% in model group, P<0.01). Oral administration of SAA improved the ECG performance of Σ-ST from 30-190 min after ischemia (P<0.05-0.01), while intravenous SAA had a rapid onset (10-190 min after ischemia, P<0.05-0.01). Compared with model group, oral and intravenous SAA both decreased serum CK and LDH significantly (P<0.05-0.01), while the difference of intravenous administration is more significant. SAA protects myocardium in canine experimental myocardial infarction models. Intravenous administration of SAA alleviates myocardial infarction with greater significance than oral route.
丹酚酸A（SAA）是传统中药丹参中主要的水溶性活性丹酚酸之一，据报道其具有抗心肌缺血、抗氧化和抗血栓形成的作用。本研究旨在探讨急性心肌缺血（AMI）犬的合适给药途径。将24只犬随机分为四组（n = 6），即模型组、口服SAA组（8 mg•kg⁻¹）、静脉注射SAA组（4 mg•kg⁻¹）、静脉注射合心爽（0.5 mg•kg⁻¹）作为阳性药物组。通过结扎犬左冠状动脉前降支（LAD）建立AMI模型。采用心外膜心电图（ECG）测定ST段变化，用超声多普勒流量计测量冠状动脉血流量（CBF）和心肌耗氧量，用全自动生化分析仪观察血清肌酸激酶（CK）和乳酸脱氢酶（LDH）水平。用硝基蓝四氮唑（NBT）染色评估心肌梗死面积。口服和静脉注射SAA均显著降低心肌梗死面积/左心室面积[分别为（16.73±6.52）%和（13.19±2.38）%，模型组为（24.35±4.89）%，P<0.01]。口服SAA改善了缺血后30 - 190分钟的Σ-ST心电图表现（P<0.05 - 0.01），而静脉注射SAA起效迅速（缺血后10 - 190分钟，P<0.05 - 0.01）。与模型组相比，口服和静脉注射SAA均显著降低血清CK和LDH水平（P<0.05 - 0.01），但静脉注射的差异更显著。SAA在犬实验性心肌梗死模型中对心肌具有保护作用。静脉注射SAA比口服途径更能显著减轻心肌梗死。
